

# Myotonic Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

https://marketpublishers.com/r/MF87AA204EC3EN.html

Date: May 2022 Pages: 74 Price: US\$ 2,000.00 (Single User License) ID: MF87AA204EC3EN

# Abstracts

Myotonic Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

### SUMMARY

Myotonic Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Myotonic Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure



that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

#### NOTE:

This is an "on-demand" report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

Certain sections in the report may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Myotonic Dystrophy.

The pipeline guide reviews pipeline therapeutics for Myotonic Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myotonic Dystrophy therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myotonic Dystrophy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.



The pipeline guide reviews latest news related to pipeline therapeutics for Myotonic Dystrophy.

#### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Myotonic Dystrophy.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Myotonic Dystrophy pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



### **Contents**

Introduction Report Coverage Indication - Overview Indication - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Indication - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Molecule Type Indication - Companies Involved in Therapeutics Development Company 1 Company 2 Company 3 Company XX Indication - Drug Profiles Drug 1 - Drug Profiles Drug 1 - Drug Profile Product Description Mechanism of Action R&D Progress Drug 2 - Drug Profile Product Description Mechanism of Action R&D Progress Drug 3 - Drug Profile Product Description Mechanism of Action R&D Progress Drug 4 - Drug Profile Product Description
Mechanism of Action
R&D Progress
•
Drug XX - Drug Profile



Product Description Mechanism of Action R&D Progress Indication - Dormant Projects Indication - Discontinued Products Indication - Product Development Milestones Featured News & Press Releases Appendix Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us



# **List Of Tables**

#### LIST OF TABLES

Number of Products under Development for Indication, 2022 Number of Products under Development by Companies, 2022 Number of Products under Development by Universities/Institutes, 2022 Products under Development by Companies, 2022 Products under Development by Universities/Institutes, 2022 Number of Products by Stage and Target, 2022 Number of Products by Stage and Mechanism of Action, 2022 Number of Products by Stage and Route of Administration, 2022 Number of Products by Stage and Molecule Type, 2022 Indication - Pipeline by Company 1, 2022 Indication - Pipeline by Company 2, 2022 Indication - Pipeline by Company 3, 2022 Indication - Pipeline by Company XX, 2022 Indication - Dormant Projects, 2022



# **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Indication, 2022 Number of Products under Development by Companies, 2022 Number of Products under Development by Universities/Institutes, 2022 Number of Products by Top 10 Targets, 2022 Number of Products by Stage and Top 10 Targets, 2022 Number of Products by Top 10 Mechanism of Actions, 2022 Number of Products by Stage and Top 10 Mechanism of Actions, 2022 Number of Products by Routes of Administration, 2022 Number of Products by Stage and Routes of Administration, 2022 Number of Products by Top 10 Molecule Types, 2022



### I would like to order

Product name: Myotonic Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Product link: https://marketpublishers.com/r/MF87AA204EC3EN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/MF87AA204EC3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Myotonic Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players